Difference between revisions of "Olaratumab (Lartruvo)"
m |
|||
| Line 1: | Line 1: | ||
=General information= | =General information= | ||
| − | Class/mechanism | + | Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.<ref name="insert">[http://pi.lilly.com/us/lartruvo-uspi.pdf Olaratumab (Lartruvo) package insert]</ref><ref>[[Media:Olaratumab.pdf | Olaratumab (Lartruvo) package insert (locally hosted backup)]]</ref><ref>[http://lartruvo.com/ Lartruvo manufacturer's website]</ref><ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=626630 NCI Drug Dictionary entry for olaratumab]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
<br> | <br> | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Ewing's sarcoma]] | *[[Ewing's sarcoma]] | ||
*[[Sarcoma|Soft tissue sarcoma]] | *[[Sarcoma|Soft tissue sarcoma]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *Brief patient counseling information can be found in the [http://pi.lilly.com/us/lartruvo-uspi.pdf Olaratumab (Lartruvo) package insert] <ref name="insert"></ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *10/19/2016: | + | *10/19/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526087.htm FDA approved] "for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate." |
| + | |||
| + | ==Also known as== | ||
| + | LY3012207, IMC-3G3, anti-PDGFR alpha monoclonal antibody IMC-3G3, anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3 | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 16:33, 21 October 2016
General information
Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found in the Olaratumab (Lartruvo) package insert [1]
History of changes in FDA indication
- 10/19/2016: FDA approved "for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate."
Also known as
LY3012207, IMC-3G3, anti-PDGFR alpha monoclonal antibody IMC-3G3, anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3